NIH/NIAID Pharmacological Approaches to Evaluating Drug Regimens to Address Antimicrobial Resistance (R01)

Contribute to Research on Drug Resistance...

Preventing and managing clinical antimicrobial drug resistance is of principal interest for NIH and for NIAID in particular. A recent funding opportunity announcement (FOA) targets this research priority. Consider applying if your research can add to the understanding of biological and pharmacological factors underlying the effectiveness of concomitant or sequential drug regimens used against drug-resistant infectious diseases. Proposed studies should include collaborative approaches designed to investigate the interactions between host, drug combinations or sequential drug administrations, and pathogen in affected tissues. While studies on drug regimens are the primary focus of this initiative, you may also propose research on an individual drug that is currently used clinically as single-drug therapy for a particular diagnosis of drug-resistant disease. Note that this FOA will not support research on new targets, models, or on HIV/AIDS.

Participating Organization(s)	National Institutes of Health (NIH)
Components of Participating Organizations	National Institute of Allergy and Infectious Diseases (NIAID)
Funding Opportunity Title	Pharmacological Approaches to Evaluating Drug Regimens to Address Antimicrobial Resistance  (R01)
Activity Code	R01 Research Project Grant
Announcement Type	New
Related Notices	May 1, 2013 - See Notice NOT-AI-13-042. Notice of Correction to Award Information.
Funding Opportunity Announcement (FOA) Number	RFA-AI-13-024
Number of Applications	See Section III. 3. Additional Information on Eligibility.
Catalog of Federal Domestic Assistance (CFDA) Number(s)	93.855, 93.856
Funding Opportunity Purpose	The purpose of this FOA is to support antimicrobial pharmacokinetic and pharmacodynamic (PK/PD) studies of drug combinations or sequentially administered (sequenced) antimicrobial agents in relevant in vitro and animal models to enhance understanding of the host, drug and microbial factors that contribute to the emergence of antimicrobial drug resistance in clinically relevant pathogens with a goal of minimizing the potential for development of resistance. A secondary objective is to establish partnerships among anti-microbial pharmacologists, microbiologists and animal modelers to bridge the gap between antimicrobial pharmacology and its application to fundamental and translational research for the clinical management of drug resistance.

Key Dates

Open Date (Earliest Submission Date)	June 30, 2013
Letter of Intent Due Date(s)	June 30, 2013
Application Due Date(s)	July 30, 2013, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Scientific Merit Review	November, 2013
Advisory Council Review	January, 2014
Earliest Start Date	March, 2014

Part 1. Overview Information
Part 2. Full Text of the Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information